Circulating concentrations of insulin-like growth factor-I and risk of breast cancer

Lancet

Volumn 351, Issue 9113, 1998, Pages 1393-1396

  Hankinson, Susan E ^a,b,d   Willett, Walter C ^a,b   Colditz, Graham A ^a,b   Hunter, David J ^a,b   Michaud, Dominique S ^a,b   Deroo, Bonnie ^c   Rosner, Bernard ^a   Speizer, Frank E ^a   Pollak, Michael ^c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c MCGILL UNIVERSITY   (Canada)

^d CHANNING LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ADULT; ARTICLE; BREAST CANCER; BREAST EPITHELIUM; CANCER RISK; CELL PROLIFERATION; CONTROLLED STUDY; EPITHELIUM CELL; FEMALE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; REGRESSION ANALYSIS;

EID: 0032499440     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(97)10384-1     Document Type: Article

References (36)

1. 1 Yang XF, Beamer WG, Huynh HT, Pollak M. Reduced growth of human breast cancer xenografts in hosts homozygous for the lit mutation. Cancer Res 1996; 56: 1509-11.
2. 2 Pollak M, Constantino J, Polychronakos C, et al. Effect of tamoxifen on serum insulin-like growth factor I levels in stage I breast cancer patients. J Natl Cancer Inst 1990; 82: 1693-97.
3. 3 Arteaga CL, Kitten LJ, Coronado EB, et al. Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice. J Clin Invest 1989; 84: 1418-23.
4. 4 Ng ST, Zhou J, Adesanya OO, Wang J, LeRoith D, Bondy CA. Growth hormone treatment induces mammary gland hyperplasia in aging primates. Nat Med 1997; 3: 1141-44.
5. 5 Tornell J, Carlsson B, Pohjanen P, Wennbo H, Rymo L, Isaksson OGP. High frequency of mammary adenocarcinomas in mettallothionein promoter-human growth hormone transgenic mice created from two different strains of mice. J Steroid Biochem Mol Biol 1992; 43: 237-42.
6. 6 Hadsell DL, Greenberg NM, Fligger JM, Baumrucker CR, Rosen JM. Targeted expression of des (1-3) human insulin-like growth factor I in transgenic mice influences mammary gland development and IGF-binding protein expression. Endocrinology 1996; 137: 321-30.
7. 7 Bates P, Fisher R, Ward A, Richardson L, Hill DJ, Graham CF. Mammary cancer in transgenic mice expressing insulin-like growth factor II (IGF II). Br J Cancer 1995; 72: 1189-93.
8. 8 Chen NY, Chen WY, Striker LJ, Striker GE, Kopchick JJ. Coexpression of bovine growth hormone (GH) and human GH antagonist genes in transgenic mice. Endocrinology 1997; 138: 851-54.
9. 9 Ruan W, Knapp J, Chen W, Kopchick JJ, Kleinberg DL. Mammary gland development is impared in transgenic mice overexpressing a bovine growth hormone antagonist. Proceedings of the Endocrine Society 79th Annual Meeting, 1997; 79: 165 (abstr).
10. 10 Sinha YN, Vlahakis G, VanderLaan WP. Serum, pituitary and urine concentrations of prolactin and growth hormone in eight strains of mice with varying incidence of mammary tumors. Int J Cancer 1979; 24: 430-37.
11. 11 Juul A, Bang P, Hertel NT, et al. Serum insulin-like growth factor I in 1030 healthy children, adolescents, and adults: relation to age, sex, stage of puberty, testicular size, and body mass index. J Clin Endocrinol Metab 1994; 78: 744-52.
12. 12 Juul A, Dalgaard P, Blum WF, et al. Serum levels of insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) in healthy infants, children, and adolescents: the relation to IGF-I, IGF-II, IGFBP-1, IGFBP-2, age, sex, body mass index and pubertal maturation. J Clin Endocrinol Metab 1995; 80: 2534-42.
13. 13 Cohen SM, Ellwein LB. Cell proliferation in carcinogenesis. Science 1990; 249: 1007-11.
14. 14 Hankinson SE, Willett WC, Manson JE, et al. Alcohol, height, and adiposity in relation to estrogen and prolactin levels in postmenopausal women. J Natl Cancer Inst 1995; 87: 1297-302.
15. 15 Goodman-Gruen D, Barrett-Conner E. Epidemiology of insulin-like growth factor-I in elderly men and women. Am J Epidemiol 1997; 145: 970-76.
16. 16 Campagnoli C, Biglia N, Altare F, et al. Differential effects of oral conjugated estrogens and transdermal estradiol on insulin-like growth factor I, growth hormone and sex hormone binding globulin serum levels. Gynecol Endocrinol 1993; 7: 251-58.
17. 17 Jones J, Clemmons DR. Insulin like growth factors and their binding proteins-biological actions. Endocr Rev 1995; 16: 3-34.
18. 18 Bruning PF, Van Doom J, Bonfrär JMG, et al. Insulin-like growth-factor-binding protein 3 is decreased in early-stage operable premenopausal breast cancer. Int J Cancer 1995; 62: 266-70.
19. 19 Rosner B. Multivariate methods in ophthalmology with application to other paired-data situations. Biometrics 1984; 40: 1025-35.
20. 20 Hosmer DW, Lemeshow S. Applied logistic regression. New York: Wiley, 1989.
21. 21 Peyrat JP, Bonneterre J, Hecquet B, et al. Plasma insulin-like growth factor-I (IGF-I) concentrations in human breast cancer. Eur J Cancer 1993; 29A: 492-97.
22. 22 Ruan W, Catanese V, Wieczorek R, Feldman M, Kleinberg DL. Estradiol enhances the stimulatory effect of insulin-like growth factor-I (IGF-1) on mammary development and growth hormone-induced IGF-1 messenger ribonucleic acid. Endocrinology 1995; 36: 1296-302.
23. 23 Ruggeri B, Klurfeld D, Kritchevsky D, Furlanetto RW. Calorie restriction and 7,12-dimethylbenz(a)anthracene-induced mammary tumor growth in rats: alterations in circulation insulin, insulin-like growth factors I and II, and epidermal growth factor. Cancer Res 1998; 49: 4135-41.
24. 24 Michels KB, Trichopoulos D, Robins JM, et al. Birthweight as a risk factor for breast cancer. Lancet 1996; 348: 1542-46.
25. 25 Ekbom A, Trichopoulos D, Adami HO, Hsieh CC, Lan SJ. Evidence of prenatal influences on breast cancer risk. Lancet 1992; 340: 1015-18.
26. 26 Osorio M, Torres J, Moya F, et al. Insulin-like growth factor (IGFs) and IGF binding proteins -1, -2 and -3 in newborn serum: relationships to fetoplacental growth at term. Early Hum Dev 1996; 46: 15-26.
27. 27 Hunter DJ, Willett WC. Diet, body size and breast cancer. Epidemiol Rev 1993; 15: 110-32.
28. 28 Chan JM, Stampfer MJ, Giovannucci E, et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998; 279: 563-65.
29. 29 Cats A, Dullaart RPF, Kleibeuker JH, et al. Increased epithelial cell proliferation in the colon of patients with acromegaly. Cancer Res 1996; 56: 523-26.
30. 30 Pollak M. Endocrine effects of insulin-like growth factor 1 on normal and transformed breast epithelial cells: potential relevance to strategies for breast cancer treatment and prevention. Breast Cancer Res Treat 1998; 47: 209-17.
31. 31 Zarandi M, Horvath JE, Halmos G, et al. Synthesis and biological activities of highly potent antagonists of growth hormone-releasing hormone. Proc Natl Acad Sci USA 1994; 91: 12298-302.
32. 32 Pollak MN, Schally AV. Mechanisms of antineoplastic action of somatostatin analogues. Proc Soc Exp Biol Med 1998; 217: 143-52.
33. 33 Pollak M, Ingle J, Suman V, Kugler J. Rational for combined antiestrogen-somatostatin analogue therapy of breast cancer. In: Salmon SE, ed. Adjuvant therapy of cancer VIII: proceedings of the eighth international conference on the adjuvent therapy of cancer. Philadelphia: JB Lippincott, 1996: 145-53.
34. 34 Gucev ZS, Oh Y, Kelley KM, Rosenfeld KG. Insulin-like growth factor binding protein 3 mediates retinoic acid and transforming growth factor beta 2-induced growth inhibition in human breast cancer cells. Cancer Res 1996; 56: 1545-50.
35. 35 Oh Y, Muller HL, Ng L, Rosenfeld RG. Transforming growth factor-induced cell growth inhibition in human breast cancer cells is mediated through insulin-like growth factor-binding protein-3 action. J Biol Chem 1995; 270: 13589-92.
36. 36 Rozen F, Yang X, Huynh H, Pollak M. Antiproliferative action of vitamin-D-related compounds and insulin-like growth factor binding protein 5 accumulation. J Natl Cancer Inst 1997; 89: 652-56.